Sale of the Carragelose business: Marinomed is breaking new ground with unither

Sale of the Carragelose business: Marinomed is breaking new ground with unither

The Marinomed Biotech AG, an Austrian biotechnology company, recently announced the sale of their Carragenose business to the French Unither Pharmaceuticals. This strategic decision should not only boost the company's sales, but also support the ongoing renovation.

For the sale of the Carragelose portfolio, which plays an important role in the field of medical products, Marinomed expects income of up to 20 million euros. Of these, up to 5 million euros are earmarked as a advance payment. These proceeds are important to implement the renovation plan that has already been agreed on November 14, 2024 with the company's creditors. The approval of the shareholders is obtained at an extraordinary general meeting before the deal can be finally completed.

reinforcement of the product line

unither pharmaceuticals is known as a leading company in the contract development and manufacture of medicinal products and has experience in the areas of coughing, colding and allergy products. Eric Goupil, the CEO of Unither, emphasizes the opportunities that are offered by the integration of the Carrelose products. At the same time, the development of new products such as Carragelose eye drops should also be promoted.

Andreas Grassauer, CEO of Marinomed, emphasizes that the partnership with Unither is an excellent opportunity for the Carragelose portfolio. The cooperation plans include a service contract to secure the transition period after the products are transferred. Thanks to this strategic alliance, innovative solutions are to be developed for customers who convince both in quality and effectiveness.

Carragelose is a special polymer of red algae and has proven to be effective in the prevention of respiratory diseases. It forms a protective layer on the mucous membrane that prevents viruses from entering like Sars-Cov-2. Marinomed holds the patent rights on this product and has secured sales rights in several important markets.

The Marinomed Biotech AG, which is based in Korneuburg, is noted on the Vienna Stock Exchange and is constantly looking for innovative solutions in the areas of immunology and virology. Financing through the sale of the Carragelose business is intended to further promote the development of the Marinosolv platform and to set up the company well for the future.

Information on ongoing developments and the upcoming general meeting can be found on the official website of Marinomed Biotech AG. The sale of the Carragelose business indicates a targeted realignment of the company, which takes into account both current market conditions and future growth opportunities.